Alpha Tau Medical Ltd. (DRTS) Total Debt to Capital

Alpha Tau Medical Ltd. (DRTS) is developing an exclusive alpha-radiation system for the targeted removal of dense neoplasms, creating a robust defensive barrier against market competitors. This chart illustrating the asset's market value on GURU.Markets shows a figure of 0.33, complementing data on the creation of energy-efficient oncology systems that minimize the use of toxic components. The brand's high status is further validated by the recognition of its diffusion therapy method, which ensures a gentle impact on healthy cells.

Total debt-to-equity measures the proportion of borrowed funds relative to owned assets, determining the financial stability and degree of credit dependence of a business. For Alpha Tau Medical Ltd. (DRTS), this balance is critical due to its reliance on sales of a single alpha-therapy platform. By analyzing changes in the total debt-to-equity ratio, an investor assesses the company's ability to fund expansion across US clinics. An upward trend in the curve signals the risk of excessive interest payments, while a stable metric confirms the viability of the single-product model.